
Pharmacovigilance Risk Assessment & Risk Mitigation Strategy Builder
Build comprehensive drug safety risk assessments and mitigation strategies
What You Can Do
This skill systematically evaluates pharmacovigilance risks across drug development and post-market surveillance, generating detailed risk matrices, monitoring plans, and regulatory recommendations. You can identify potential safety signals, quantify risk severity and likelihood, prioritize concerns by clinical impact, and propose evidence-based mitigation strategies tailored to your therapeutic area and patient population. Output includes risk stratification, surveillance protocols, and documentation ready for regulatory submissions.
Features
Systematically uncover potential safety signals, adverse events, and product-specific risks based on mechanism of action, patient population, and therapeutic indication
Quantify each risk using industry-standard rating scales and combine scores into actionable priority rankings
Rank risks by clinical, regulatory, and business impact to focus mitigation efforts where they matter most
Generate targeted, implementable risk control measures including baseline assessments, enhanced monitoring, and risk minimization tools
Create monitoring protocols, signal detection methods, and assessment schedules aligned with your product lifecycle
Align risk assessments with FDA, EMA, ICH, and other regulatory pharmacovigilance requirements and guidance
Produce professional risk assessment reports, Risk Management Plans, and healthcare provider communications
Example Output
Risk Assessment Summary: [DRUG_NAME]
Identified Risks: 12 | High Priority: 4 | Medium Priority: 5 | Low Priority: 3
Risk Matrix
| Risk | Severity | Likelihood | Priority | Key Mitigation |
|---|---|---|---|---|
| Hepatotoxicity | High | Medium | HIGH | Baseline/monthly LFTs, contraindications in liver disease |
| QT Prolongation | High | Low | HIGH | ECG screening, dose adjustment guidance, drug interaction warnings |
| Drug-Drug Interactions | Medium | High | HIGH | Provider education, CYP3A4 inhibitor contraindications |
Recommended Mitigation Strategies
- Pre-treatment Baseline Assessment — LFT panel, 12-lead ECG, concomitant medication review
- Enhanced Monitoring Program — Monthly LFTs × 3 months, then quarterly; periodic ECG in high-risk patients
- Healthcare Provider Education — Safety data sheet, dose adjustment guidelines, interaction checklist
- Patient Risk Minimization — Medication guide, symptom recognition, when-to-report guidance
- Pharmacovigilance Plan — Monthly adverse event review, quarterly safety summaries, signal detection protocol
What's Included
- Risk identification framework: Structured templates for capturing known and potential safety issues from clinical data, similar products, and mechanism-of-action analysis
- Risk scoring and prioritization matrices: Industry-standard evaluation tools combining severity, likelihood, and clinical/regulatory impact into actionable rankings
- Mitigation strategy templates: Pre-built approaches for common pharmaceutical risks: enhanced monitoring, baseline assessments, provider education, patient communications
- Regulatory compliance guide: Mapping to FDA Risk Management Plans, EMA guidelines, ICH pharmacovigilance standards, and PRAC submission requirements
- Pharmacovigilance planning tools: Signal detection protocols, safety review schedules, adverse event monitoring checklists, and periodic safety update templates
Who It's For
- Drug safety professionals and pharmacovigilance specialists managing post-market surveillance and safety monitoring
- Regulatory affairs managers preparing risk management submissions and compliance documentation for agencies
- Clinical development teams designing safety assessments and monitoring protocols during drug trials
- Risk management executives evaluating product safety profiles for commercial and strategic decisions
Best For
- Pre-launch comprehensive risk assessments before commercial product release
- Ongoing signal detection and systematic monitoring of emerging safety trends post-market
- Regulatory Risk Management Plan submissions to FDA, EMA, and international health authorities
- Risk communication including safety updates, healthcare provider alerts, and patient educational materials






